Fabry Disease Treatment Market Growth & Trends
The global fabry disease treatment market size is estimated to reach a value of USD 4.93 billion by 2030, exhibiting a CAGR of 9.9% from 2024 to 2030. Rising cohort of Fabry disease, increasing adoption of novel therapies such as chaperone treatment, and potential approval of pipeline drugs including substrate reduction therapies and enzyme replacement therapies are providing a fillip to the market.
Fabry disease is a rare inherited lysosomal storage disorder caused by genetic mutation that interferes with function of alpha galactosidase enzyme. Fabry disease generally has a late onset with mild symptoms, due to which several patients are often undiagnosed. Standard of care for management of the disease is enzyme replacement therapy (ERT). Sanofi’s Fabrazyme and Shire’s Replagal are the only approved ERTs in the EU; however in the U.S., only Fabrazyme has been approved.
Focus of current clinical trials is to improve the safety and efficacy profile of ERTs and introduction of novel oral therapies that can eliminate the need for intravenous infusions. Recently, Amicus Therapeutics’ Galafold has been approved as the first oral chaperone therapy for the treatment of adults in the U.S., Canada, EU, Japan, Australia, Israel, and South Korea.
North America held the largest share in the Fabry disease treatment market in 2017, followed by Europe. The growth of the region can be attributed to higher adoption of novel therapies, favorable reimbursement policies, and better healthcare facilities. However, high cost of therapy with ERTs such as Fabrazyme is an impediment for the market in developing regions.
Fabry Disease Treatment Market Report Highlights
- Intravenous route dominated the market with a market share of 65.9 % in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2030.
- The enzyme replacement treatment segment dominated the market and accounted for a share of 72.3 % in 2023.
- North America commanded the leading market share of more than 45.1% in the Fabry disease treatment market, followed by Europe, in 2023
- APAC is likely to witness the fastest growth during the forecast period, followed by Latin America, due to increasing healthcare expenditure and rising patient population
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Fabry Disease Market Variables, Trends, & Scope
Chapter 4. Fabry Disease Market: Treatment Estimates & Trend Analysis
Chapter 5. Fabry Disease Market: Route of Administration Estimates & Trend Analysis
Chapter 6. Fabry Disease Market: Distribution Channel Outlook Estimates & Trend Analysis
Chapter 7. Fabry Disease Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
Companies Mentioned
- Sanofi S.A.
- Shire PIc.
- Amicus Therapeutics Inc.
- ISU Abxis Co Ltd.
- JCR Pharmaceuticals Co Ltd.
- Protalix Biotherapeutics Inc.
- Idorsia Pharmaceuticals Ltd.
- Avrobio Inc.
- Takeda Pharmkceutical Co Ltd.
- Chiesi Farmaceutici SpA
- Freeline Therapeutics Holdings PLC
- Yuhan Corp
- MOP Therapeutics
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 2.54 Billion |
| Forecasted Market Value ( USD | $ 4.93 Billion |
| Compound Annual Growth Rate | 9.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
